Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue
about
Using nonhuman primates to model HIV transmissionA Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex VivoVaginal drug distribution modelingPharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infectionExposure to MIV-150 from a high-dose intravaginal ring results in limited emergence of drug resistance mutations in SHIV-RT infected rhesus macaquesEngineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancyTopical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-Intravaginal Rings Protects Macaques from Multiple SHIV ExposuresRecent Insights into the HIV/AIDS Pandemic.Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.Why primate models matter.Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies.Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trialHistorical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.Herpes simplex virus type-2 stimulates HIV-1 replication in cervical tissues: implications for HIV-1 transmission and efficacy of anti-HIV-1 microbicidesTopical microbicides and HIV prevention in the female genital tractPreclinical evaluation of the immunomodulatory lymphocyte trafficking drug FTY720 for HIV prevention in the female genital mucosa of macaquesIncreased susceptibility to vaginal simian/human immunodeficiency virus transmission in pig-tailed macaques coinfected with Chlamydia trachomatis and Trichomonas vaginalisEvaluation of Rapidly Disintegrating Vaginal Tablets of Tenofovir, Emtricitabine and Their Combination for HIV-1 Prevention.Effect of tenofovir on nucleotidases and cytokines in HIV-1 target cells.An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaquesMIV-150/zinc acetate gel inhibits cell-associated simian-human immunodeficiency virus reverse transcriptase infection in a macaque vaginal explant model.Macaque models of enhanced susceptibility to HIV.Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaquesShort Communication: Practical Experience with Analysis and Design of Repeat Low-Dose SHIVSF162P3 Exposure Studies in Female Pigtail Macaques with Varying Susceptibility During Menstrual Cycling.Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infectionProtection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.A single dose of a MIV-150/Zinc acetate gel provides 24 h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24 h after gel use.The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection.Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques.In search of the optimal delivery method for anti-HIV microbicides: are intravaginal rings the way forward?Nondaily preexposure prophylaxis for HIV prevention.An Intravaginal Ring for the Simultaneous Delivery of an HIV-1 Maturation Inhibitor and Reverse-Transcriptase Inhibitor for Prophylaxis of HIV TransmissionOvercoming pharmacologic sanctuaries.Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse ModelAnimal models for microbicide safety and efficacy testing.Safety and Pharmacokinetics of Quick-Dissolving Polymeric Vaginal Films Delivering the Antiretroviral IQP-0528 for Preexposure Prophylaxis.
P2860
Q26861425-4DFFEEE3-4BA8-4664-9065-B0C817760E35Q27334384-E038FD10-A2BA-4476-A391-9F13621753AEQ28088306-E4C4F628-F85E-48FE-8B71-E2810D98F661Q28481276-EB81844A-5136-42EE-B1D6-074F071CBF75Q28540200-4AF4C345-611B-4088-9C84-CD98EA0FE429Q28540419-4084F0C2-6322-4BC1-9C80-AEFA9023DF8FQ28550108-928998A2-A4FB-43B2-935F-DBD329175445Q30235024-BB439094-8D1E-44FB-8D65-F1880DCFD58EQ30412592-F2C2CBB3-7457-49CA-9B1A-E06CDE52157BQ30417520-22AD0603-7CDC-4A4A-86A6-A653A0978BF6Q30447923-C1133356-027C-45B3-9F31-7F8E7823F4A3Q33684387-EC5A2359-D40C-4D06-A902-6CA25EC700CBQ33821090-CF43FB39-81C6-4FAF-8EA8-6D782D79B468Q34034418-2000A5B3-1FF3-4366-A018-500C784C34B1Q34057568-3FDC975E-223F-43BB-9BA9-E9ED81156F59Q34064986-7EE714C4-1374-4BE3-BF7A-97EB5B283110Q34086820-A3D8158F-C52D-47B6-AE23-D7B8A1F64A16Q34478248-9A1FCCF4-11BC-446A-BAB7-34C9ABD91720Q34736553-0A611D4B-ABF5-407E-9B73-416C22B84C19Q34785687-FC460D5B-F0D2-4A99-9CE4-CE92815C53F9Q35036745-195FBD99-2B1C-495A-85FC-20557913A023Q35345363-3DB4FBD4-D637-4CEF-9D8F-17B320E7FC47Q35746218-D6FE94B5-A32D-46EE-98D8-A28331C5F942Q35776556-7A3C1238-1892-417E-BE31-F3ECFE77891FQ35861437-61112171-3480-49FE-9DFB-9BF2C18F2EB1Q35927290-66A40E5E-5434-492A-A484-F6575E8648BFQ36259499-F549675C-86B5-4D7D-BD2A-ED9061E8B09DQ36281109-130D3CE9-7D20-4EA8-9099-9C8B504B9A53Q36286901-8DAA7EEC-8741-41AA-8DB3-413A777F053BQ36306935-237291DD-71A3-48C6-BAB1-E39528211B2DQ36359120-72CE5055-4E1C-4DEC-88A1-002B2178D0B2Q36359133-2F28CBE8-4A34-4D26-8A19-9A1B50356158Q36364164-92FEF699-3706-4460-BDC9-FD51669DBBAFQ36630547-6D0CA55B-3F55-4BE9-81FE-36DE8D8DEE2BQ36669377-76B610C6-B98C-470D-B5BC-2CB7599A1156Q36770118-3433313E-AF40-4385-A58F-25D30DCE7489Q36915933-A01A4796-571E-43F8-A3BE-DC25A8C17C90Q36933427-8978BD35-2B17-4D2A-883C-B0B61C5E37A7Q36989915-6826FBB8-9EBB-4517-BC56-59F2CF3FB251Q37023114-217EF1A7-6ED9-4679-B26D-C79E93EE3B9F
P2860
Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Durable protection from vagina ...... nship to drug levels in tissue
@ast
Durable protection from vagina ...... nship to drug levels in tissue
@en
type
label
Durable protection from vagina ...... nship to drug levels in tissue
@ast
Durable protection from vagina ...... nship to drug levels in tissue
@en
prefLabel
Durable protection from vagina ...... nship to drug levels in tissue
@ast
Durable protection from vagina ...... nship to drug levels in tissue
@en
P2093
P2860
P356
P1433
P1476
Durable protection from vagina ...... nship to drug levels in tissue
@en
P2093
Amy Martin
Angela Holder
Charles Dobard
Chou-Pong Pau
Debra L Hanson
Francis J Novembre
J Gerardo García-Lerma
James Smith
Jonathan Lipscomb
Sunita Sharma
P2860
P304
P356
10.1128/JVI.05842-11
P407
P577
2011-11-09T00:00:00Z